nonidentical marrow are alive and well without treatment 1.5 t o 13 years after transplantation (median, 6.5 years). No manifestations of accelerated phases have occurred in these seven patients, and significant natural killer activity is detectable. Interestingly, BMT prevented recurrence of accelerated phases in patients with l i m i t e d numbers of donor-type leukocytes after transplantation. Ocular and cutaneous albinism were not corrected after transplantation. None of the patients developed serious toxic reactions to the BMT conditioning regimen or have long-term sequelae. These results show that HLA-identical BMT is an acceptable curative treatment for Chediak-Higashi syndrome, whereas HLA-nonidentical BMT remains an experimental approach. Once accelerated phases have occurred, the disease is invariably fatal before the use of etoposide (VP-16) combined with steroids and intrathecal methotrexate.'3 However, remissions are transient,**" and relapses become increasingly insensitive to treatment; patients eventually die of bleeding complications and infections.
Bone marrow transplantation (BMT) has been proposed in these cases because it has been shown to revert the leukocyte disorder of beige mice, a model of CHS.I4 There have been several reports of successful BMT in CHS patients with no recurrence of accelerated phase^.'^,'^"^ We report the results of BMT in 10 children with CHS, emphasing long-term outcome.
MATERIALS AND METHODS

Patients
We reviewed the cases of I O consecutive patients with CHS who underwent a total of 12 allogenic BMTs in two centers (HBpital des Enfants Malades or HBpital Robert DebrC, Paris, France). The diagnosis of CHS was based on an association of partial oculocutaneous albinism with characteristic findings,' detection of enlarged granulations in blood leukocytes,' and defective NK cell activity.'"
As shown in Table 1 , age at diagnosis varied from 2 months to IO years (median, 32 months). Age at BMT varied from 4 months to 126 months (median, 37 months). The median time between diagnosis and BMT was 7 months (range, 2 to 19 months). Diagnosis was facilitated by the following features: consanguinity (n = 7). presence of an affected sibling (n = l), repeated bacterial infections (n = 4), and accelerated phases (n = 5). Hypopigmentation of the skin was noticed in all patients except patient 7, and thin hair with silvery tint was observed in all patients. Ocular symptoms including photophobia and/or hypopigmentation of iris and retina andor nystagmus were noticed in all patients except patient 7. Three patients had severe neurologic manifestations, including blindness associated with abnormal chiasma on the chromatography (CT) scan, cerebellar ataxia (n = l), and a slight delay in milestone acquisition (n = 2).
Neutropenia (less than I,OOO/pL) was present in seven patients, and the five patients tested had reduced granulocyte chemotaxis. All patients had typical enlarged granulations in blood leukocytes. Thrombocytopenia (< 15O,OOO/pL) and anemia (< IO g/dL) were Abbreviation: BCG, Calrnette-GuBrin bacillus. present in four patients (Table 2) . Cytotoxic T-cell activity was reduced in four of four cases (data not shown). The activity of NK cells was profoundly decreased in all cases (see Table 4 ). Cases 1 through 4, 9, and 10 have previously been described in detail." Patient 7 was considered to have CHS because of the detection of typical granulations in blood leukocytes and thin hair with silvery tint, despite the absence of detectable ocular albinism.
The accelerated phase was defined as the association of persistent fever with hepatosplenomegaly, pancytopenia, low fibrinogen level, increased liver enzyme activity, and hypertriglycerideAccelerated phase occurred in all patients before BMT except in patients 1 and 5. Patient 1 relapsed with an accelerated phase between the first and the second BMT. Accelerated phases were successfully treated by intravenous infusion of VP-16, steroids, and intrathecal meth~trexate,'~ although they recurred in two patients. Except for patient 4, BMT was performed in complete remission from an accelerated phase (Table 2) . Accelerated phases were associated with Epstein-Barr virus (EBV) infection in patient 6 and Rickettsia conori in patient 8. In the seven other cases, no pathogen was detected. mia,1.8.13
BMT HLA-identical BMT. Seven patients received nine marrow collections from HLA A,B,DR-identical, mixed lymphocyte reactionnegative siblings (n = 4) or parents (n = 3) ( Table 2 ). Conditioning regimen consisted of VP-16 [300 mg/m' intravenously (IV) on days -12 through -101, busulfan (4 mgkg on days -9 through -6), and cyclophosphamide (Cy; 50 mgkg on days -5 through -2). with the following exceptions. Patient 7 received a total dose of VP-16 of 400 mg/m* before the first and second BMT, busulfan 20 mgkg before the first BMT, and 26 mgkg of busulfan and horse ATG before the second BMT. Patient 1 received only Cy (200 mgkg total dose) before the first BMT and Cy (100 mgkg total dose) and total body irradiation (7 Gy with lung shielding to 3.5 Gy) before the second BMT.I5 VP-16 was added to the conventional busulfan/ Cy regimen because of its efficacy in familial hemophagocytic lymphohistiocytosis, a syndrome analogous to CHS?''.'' presumably due to its activity against activated lymphocytes and monocytes/ macrophages.
Patient 2 received marrow T cell-depleted by E-rosetting. All other matched patients received unmanipulated marrow.
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine (3 mgikg/d as a continuous IV infusion, then 3 mgkgl d orally from day 60 for 6 months) combined with methotrexate (10 mg/m' on days + l , 3, 6, and 11), except for in the case of patient 1, who received only methotrexate (days + 1,3,6, and 1 1 and weekly until day 90).
HLA-nonidentical BMT. Three patients received HLA-nonidentical marrow from a single antigen-mismatched sibling (patients 8 and 10) or a haplotype-mismatched parent (patient 9) ( Table 2 ).
The conditioning regimen was the same as for recipients of HLAidentical marrow, except in the case of patient 10, who also received cytosine arabinoside (1 g/m' at days -1 1 and -10, while VP-16 was given at days -14 through -12) because of persistent neurologic manifestations of an accelerated phase. (presence of lymphoblasts). All nonidentical patients received marrow that was T cell-depleted by E-rosetting. Cylosporine (3 mg/kg/d) was infused for 60 days. To prevent graft rejection, patient 8 also received two mouse monoclonal antibodies specific for lymphocyte function-associate antigen 1 (LFA-I; Pasteur Merieux, Lyon, France) and CD2 (Innova, BesanFori, France) by the IV route from days -3 through + I O (0.2 mg/ Wd).
All patients were placed in sterile isolators or laminar-air-flow rooms. They underwent gut decontamination by means of nonabsorbable antibiotics and received weekly IV infusions of Ig. Parents gave their informed consent to the procedure in every case. The last evaluation was made on December 31, 1993.
For Cy was given as IV injection 3 mgkgld from day -1 to day 60, then orally 3 mg/kg/d from day M) to day 180. MTX was given as IV injection: 10 mg/mz on days +l, Abbreviations: AP, accelerated phase; MLR, mixed lymphocyte reactivity: ag, antigen; MTX. methotrexate: Endoxan: Cy, cyclosporine; TBI, total body irradiation. " 3, 6. and 11. Mouse monoclonal antibodies anti-LFA-l and anti-CD2 were given by IV route from day -3 to day + l 0 (0.2 mgkgldl.
Laboratory Methods
Chimerism was assessed by determining the fraction of leukocytes with typical abnormal granulations on blood smears, immunoglobulin allotyping, erythrocyte phenotyping, HLA typing (when donor was HLA-incompatible), and the use of a Y chromosome-specific probe in Southern blot analysis (provided by Dr Drouard and Prof Nessmann, Paris, France) or polymerase chain reaction ( K R ) amplification of leukocyte DNA with microsatellite probes (provided by Prof Jeannet, Geneva, Switzerland).
NK activity was measured using K562 cells as targets in a "Crrelease assay.'"
RESULTS
Engraftment, Complications, and Outcome
HLA-identical BMT. Engraftment was achieved in six of seven HLA-identical transplants, after two attempts in patient 1 (probably because of insufficient conditioning). Despite the use of a conditioning regimen in patient 7 similar to that received by the other patients, stable engraftment could not be obtained, and he died 2 years later of accelerated phase progression ( Table 3) .
The kinetics of hematologic lineage development were unremarkable in the patients who were successfully engrafted. The median day to an absolute neutrophil count (ANC) of greater than 500/pL was 22 days (range, day 17 to day 31); last platelet transfusion on day 25 (range, day 12 to day 50); last erythrocyte transfusion on day 27 (range, day 15 to day 40; Table 3) .
No unusual toxicity of the conditioning regimen was noted. Mucositis was mild in all cases. Mild (grade I to 11) and transient acute GVHD occurred in five patients; none developed chronic GVHD ( infections were infrequent. Cytomegalovirus (CMV) infection occurred in patients 2, 3, and 7, but was controlled by specific therapy. Herpes simplex virus (HSV) and varicella (VZV) infections also occurred in two patients (HSV in patients 1 and 3, VZV in patients 1 and 7), both of whom recovered within 12 months after BMT. Six of the matched patients are alive and well 1.5 to 12 years after BMT ( Table  3) . No case of hepatic complication including venoocclusive disease was detected. HLA-nonidentical BMT. Engraftment of HLA-nonidentical T-cell-depleted marrow was achieved in only one of the three patients (patient 8). This patient was successfully treated for CMV infection and is alive and well 3 years after BMT. The other two patients died early after BMT from a recurrence of the accelerated phase and CMV pneumonia, respectively.
Chimerism and Disease Correction
Among the seven long-term survivors, three (patients 1, 5, and 6) exhibit full donor leukocyte chimerism, while the other four have sustained mixed chimerism, with a majority (patients 2 and 3 ) or a minority (patients 4 and 8) of donorderived cells (Table 3) . Split chimerism occurred in patient 4, in whom only host-type erythrocytes are detectable. The small proportion of donor-derived leukocytes in patients 4 and 8 has remained stable for 3 and 8 years, respectively ( Table 3) . No new accelerated phases have occurred in these seven patients, and significant NK cell activity was present in all seven patients (Table 4) For personal use only. on October 3, 2017. by guest www.bloodjournal.org From growth and development, with normal school attendance. There were no neurologic sequelae. Hair, eye, and skin albinism were not altered by BMT.
DISCUSSION
Allogeneic BMT was effective in treating the hematologic manifestations of CHS in six of seven recipients of HLAidentical marrow and one of three recipients of HLA-nonidentical marrow. This confirms and extends previous reports of BMT efficacy in CHS and in the beige mouse 1n0del.l~ In the absence of BMT, CHS is usually fatal before the age of 10 years,' although a few patients survive for more than 20 No patients with accelerated phases have survived in the absence of BMT.13 No accelerated phases have occurred during the several years of follow-up after BMT, even in patients who had limited donor-type leukocyte engraftment. This is reminiscent of patients successfully treated by means of BMT for familial hemophagocytic lymphohistiocytosis (FHL), in whom no FHL relapse occurred despite the presence of only a small proportion of donor-derived leukocytes." As the manifestations of FHL are very similar to those of the accelerated phase of CHS, it appears that a minority of normal leukocytes are sufficient to contain abnormally activated lymphocytes and macrophages in FHL and the accelerated phase of CHS, including within the CNS." Whether donorderived NK cells or other donor-derived cytotoxic leukocytes participate in the control of lymphocyte and macrophage activation remains to be determined.
Our findings indicate that aggressive BMT conditioning is not necessary, thus avoiding the risk of significant longterm sequelae. It should, however, be noted that the conditioning regimen we used did not abrogate host hematopoiesis in one patient, for reasons that are unclear. The lack of engraftment of HLA-nonidentical marrow in two of three such patients illustrates the ability of the immune systemthough deficient in NK cell activity-to induce primary graft failure in CHS. As a result, although BMT with an HLA-identical sibling or parent can be regarded as the treatment of choice in CHS, especially for patients in remission from an accelerated phase, HLA-nonidentical BMT is still an experimental procedure in this setting. The alternative of matched unrelated donor transplant can be proposed as a valuable option in the absence of a family-matched doAlthough no extrahematopoietic manifestations of CHS have occurred in the seven long-term survivors of BMT, the occurrence of mild manifestations such as peripheral or central neuropathy cannot be ruled out." Indeed, extrapyramidal manifestations have been recently reported to occur in the late-onset mild form of CHKZ3 It is unclear whether these manifestations are caused by a disease-related neurologic involvement or as CNS localization of accelerated phase.
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